Subgroup analysis of CD4+ T cell, CD8+ T cell, B cell, and IgG antibody responses in COVID-19 and non-COVID-19 participants at 4 and 24 weeks after the second BNT162b2 booster. This evidence concerns the gene CD8A and COVID-19.